CN1638801A - 芳基取代的丙醇胺衍生物与其他活性成分的联用产品及其应用 - Google Patents

芳基取代的丙醇胺衍生物与其他活性成分的联用产品及其应用 Download PDF

Info

Publication number
CN1638801A
CN1638801A CNA028163532A CN02816353A CN1638801A CN 1638801 A CN1638801 A CN 1638801A CN A028163532 A CNA028163532 A CN A028163532A CN 02816353 A CN02816353 A CN 02816353A CN 1638801 A CN1638801 A CN 1638801A
Authority
CN
China
Prior art keywords
alkyl
inhibitors
compound
formula
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028163532A
Other languages
English (en)
Chinese (zh)
Inventor
H·格隆比克
W·弗里克
H-L·舍费尔
W·克雷默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10140170A external-priority patent/DE10140170A1/de
Priority claimed from DE2001142455 external-priority patent/DE10142455A1/de
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1638801A publication Critical patent/CN1638801A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
CNA028163532A 2001-08-22 2002-08-09 芳基取代的丙醇胺衍生物与其他活性成分的联用产品及其应用 Pending CN1638801A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10140170A DE10140170A1 (de) 2001-08-22 2001-08-22 Kombinationspräparate von arylsubstituierten Propanolaminderivaten mit weiteren Wirkstoffen und deren Verwendung
DE10140170.1 2001-08-22
DE10142455.8 2001-08-31
DE2001142455 DE10142455A1 (de) 2001-08-31 2001-08-31 Kombinationspräparate von arylsubstituierten Propanolderivaten mit weiteren Wirkstoffen und deren Verwendung

Publications (1)

Publication Number Publication Date
CN1638801A true CN1638801A (zh) 2005-07-13

Family

ID=26009945

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028163532A Pending CN1638801A (zh) 2001-08-22 2002-08-09 芳基取代的丙醇胺衍生物与其他活性成分的联用产品及其应用

Country Status (21)

Country Link
US (1) US20030158094A1 (OSRAM)
EP (1) EP1420826A2 (OSRAM)
JP (1) JP2005505538A (OSRAM)
KR (1) KR20040027963A (OSRAM)
CN (1) CN1638801A (OSRAM)
AR (1) AR035284A1 (OSRAM)
BR (1) BR0211995A (OSRAM)
CA (1) CA2457974A1 (OSRAM)
CO (1) CO5560569A2 (OSRAM)
HR (1) HRP20040172A2 (OSRAM)
HU (1) HUP0401908A2 (OSRAM)
IL (1) IL160475A0 (OSRAM)
MX (1) MXPA04001256A (OSRAM)
NO (1) NO20040726L (OSRAM)
NZ (1) NZ531292A (OSRAM)
PA (1) PA8553101A1 (OSRAM)
PE (1) PE20030358A1 (OSRAM)
PL (1) PL366855A1 (OSRAM)
RU (1) RU2004108120A (OSRAM)
UY (1) UY27418A1 (OSRAM)
WO (1) WO2003018059A2 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
ES2290562T3 (es) 2001-01-26 2008-02-16 Schering Corporation Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares.
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
MXPA05004810A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de la absorcion del colesterol para el tratamiento de la desmielinizacion.
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
WO2007033372A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
CA3153292A1 (en) 2008-06-13 2009-12-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN102065942B (zh) 2008-06-20 2013-12-11 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
DK0869121T3 (da) * 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845406C2 (de) * 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
EA200100704A1 (ru) * 1998-12-23 2002-02-28 Джи.Ди.Сирл Ллс Комбинация для применения по сердечно-сосудистым показаниям

Also Published As

Publication number Publication date
MXPA04001256A (es) 2004-05-27
HUP0401908A2 (hu) 2005-01-28
UY27418A1 (es) 2002-11-29
PL366855A1 (en) 2005-02-07
JP2005505538A (ja) 2005-02-24
WO2003018059A3 (de) 2003-11-13
KR20040027963A (ko) 2004-04-01
WO2003018059A2 (de) 2003-03-06
IL160475A0 (en) 2004-07-25
US20030158094A1 (en) 2003-08-21
CO5560569A2 (es) 2005-09-30
CA2457974A1 (en) 2003-03-06
AR035284A1 (es) 2004-05-05
NO20040726L (no) 2004-02-19
PA8553101A1 (es) 2003-06-30
NZ531292A (en) 2005-08-26
HRP20040172A2 (en) 2004-10-31
RU2004108120A (ru) 2005-04-10
PE20030358A1 (es) 2003-04-23
BR0211995A (pt) 2004-09-28
EP1420826A2 (de) 2004-05-26

Similar Documents

Publication Publication Date Title
CN1638801A (zh) 芳基取代的丙醇胺衍生物与其他活性成分的联用产品及其应用
CN1304371C (zh) 杂环取代的苯甲酰脲、其药物和制备药物的用途
CN1723214A (zh) 新的氟代糖苷杂环衍生物、包含所说化合物的药品及其应用
CN1668628A (zh) 新的噻吩基糖苷衍生物、其制备方法、包含该化合物的药物及其用途
CN1222522C (zh) 二苯基氮杂环丁酮衍生物、它们的制备方法、含有这些化合物的药物和它们的用途
CN1290848C (zh) 作为治疗或预防糖尿病的二肽基肽酶抑制剂的β－氨基四氢咪唑并(1,2－A)吡嗪和四氢三唑并(4,3－A)吡嗪
CN1723212A (zh) 新型芳族氟代糖苷衍生物、包含所说化合物的药品以及其应用
CN1218936C (zh) 甲酰胺取代的苯基脲衍生物以及用于将其作为药物的制备方法
CN1286805C (zh) 酰基－4－羧基苯基脲衍生物、其制备方法及用途
CN1174980C (zh) 抑制胃酸分泌的咪唑并吡啶衍生物
CN1688555A (zh) 新的二环类激素敏感性脂酶抑制剂
CN1655792A (zh) 1,4－苯并硫杂䓬－1,1－二氧化物衍生物与其它活性成分的组合产物及其用途
CN1960989A (zh) 取代的噁唑－苯并异噻唑二氧化物衍生物、其制备方法以及其应用
CN1829715A (zh) 取代的噻唑－苯并异噻唑二氧化物衍生物、其制备方法和其用途
CN1118781A (zh) 具有抗糖尿病活性的杂环化合物及其制备和用途
CN1046162A (zh) 5-烷基喹诺酮羧酸
CN1662493A (zh) 环取代的二苯基2－吖丁啶酮、其制备方法、含有所述化合物的药物及其用途
CN1662494A (zh) 阳离子取代的二苯基2－吖丁啶酮、它们的制备方法、含有所述化合物的药物及其用途
CN101080382A (zh) 羟基联苯基羧酸和衍生物其制备方法以及它们的用途
CN1543465A (zh) 用作选择性细菌dhfr抑制剂的新的杂环化合物及其应用
CN1934090A (zh) 具有mch－调节作用的被取代的n－环己基咪唑啉酮
CN1910181A (zh) 杂环基取代的7－氨基－4－喹诺酮－3－甲酸衍生物、其生产方法及其作为药物的用途
CN1914206A (zh) 7－苯基氨基－4－喹诺酮－3－甲酸衍生物、其生产方法及其作为药物的用途
HK1076384A (en) Combined preparations, containing 1,4-benzothiepine-1, 1-dioxide derivatives and other active substances, and the use thereof
CN1671728A (zh) 新的腺苷类似物以及它们作为药物的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication